Multiple myeloma: Monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy - Monoclonal Antibodies

Multiple myeloma: Monoclonal antibodies-based immunotherapeutic strategies and targeted radiotherapy
2006 Jul
Chatterjee M, Chakraborty T, Tassone P.
Eur J Cancer.
Multiple myeloma (MM) is an incurable B-cell malignancy of terminally differentiated plasma cells. Besides conventional treatments, several targeted therapies are emerging for MM. We review recent developments in monoclonal antibodies (MoAbs) and (radio)immunoconjugates-based targeted immunotherapeutic (serotherapies) strategies, as well as skeletal targeted radiotherapy (STRtrade mark) in MM. MoAbs-based strategies include the targeting of cytokines and their receptors as well as toxins, drugs or radionuclide delivery to MM cells. Both targeted radioimmunotherapy (RIT) and STRtrade mark have proved efficient in the treatment of radiosensitive tumours. We conclude that there is a need for more mechanistic investigations of drug action to identify novel therapeutic targets in myeloma cells, as well as in the bone marrow microenvironment.
PMID: 16797969 [PubMed - in process]